Previous 10 | Next 10 |
home / stock / bvaxf / bvaxf news
Bio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study Canada NewsWire VANCOUVER, BC , June 8, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), anno...
BioVaxys and The Ohio State University Progress Pan-Sarbecovirus Vaccine Research Program Canada NewsWire Pan-Sarbecovirus Vaccines Identified by WHO as a Critical Need VANCOUVER, BC , June 3, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (F...
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30 years, researchers have been looking into the potenti...
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement Canada NewsWire VANCOUVER, BC , May 18, 2022 /CNW/ -- BioVaxys Technology Corp. ( CSE: BIOV; FRA: 5LB; ...
International Patent Application Filed for Cervical Cancer Vaccine Canada NewsWire VANCOUVER, BC , May 2, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has continued to exp...
BIOVAXYS ANNOUNCES APPOINTMENT TO BOARD OF DIRECTORS Canada NewsWire VANCOUVER , BC , April 29, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF ) ("BioVaxys" or the "Company") is pleased to announce that Mr. Anthony Dutton...
Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer remains undetected until the mutation spreads to the stomach ...
Vancouver, BC – April 25, 2022 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has entered into an agreement with the Deaconess Research Institute (“DRI”) to supply BioVa...
BioVaxys Technology (OTCQB:BVAXF) is planning to advance an investigator-sponsored Clinical Trial Application (CTA) with the European Medicines Agency this year for its colorectal cancer vaccine BVX-0922. The CTA ,if approved, will allow for the initiation of clinical study of the treatment. ...
BioVaxys Expands Cancer Vaccine Platform Canada NewsWire BVX-0922 to Target Colorectal Cancer Under Investigator-Sponsored IND VANCOUVER, BC , March 30, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ( "BioVaxys" ...
News, Short Squeeze, Breakout and More Instantly...
Biondvax Pharms Ltd Ord Company Name:
BVAXF Stock Symbol:
OTCMKTS Market:
Biondvax Pharms Ltd Ord Website:
BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT AND DEBT SETTLEMENT Canada NewsWire VANCOUVER, BC , July 23, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (" BioVaxys " or the " Company ") announ...
BIOVAXYS ANNOUNCES ISSUANCE OF DPX RELATED PATENT FROM THE U.S. PATENT AND TRADEMARK OFFICE Canada NewsWire VANCOUVER, BC , July 23, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that the United ...
Brittany Davison, CPA, CA, Joins BioVaxys as Business Advisor Canada NewsWire VANCOUVER, BC , July 18, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is pleased to announce that it has engaged Brittany Davison , ...